Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials
May help regulate appetite and feelings of fullness by slowing digestion May support metabolic processes through GLP-1 and GIP receptor pathways May contribute to weight management when combined with diet and exercise May help regulate appetite and feelings of fullness May support metabolic processes Works through GLP-1 receptor pathways *In case of a life threatening emergency, immediately call 911
They can lower both fasting and post-meal glucose levels, making them beneficial for prediabetes and overall metabolic health
Here's all you need to know To view or add a comment, sign in 1,463,826 followers
Im just okay
Relevant data from this trial have not yet been published